This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Managing Medications (MM2)

This study has been completed.
Sponsor:
Collaborator:
National Institute of Nursing Research (NINR)
Information provided by (Responsible Party):
Judith Erlen, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00222716
First received: September 14, 2005
Last updated: June 22, 2017
Last verified: June 2017
September 14, 2005
June 22, 2017
January 2004
December 2009   (Final data collection date for primary outcome measure)
Medication adherence as measured by electronic event monitors [ Time Frame: 12 weeks ]
MEMS data using AARDEX medication monitoring caps, percent daily dose correct.
Medication adherence as measured by electronic event monitors
Complete list of historical versions of study NCT00222716 on ClinicalTrials.gov Archive Site
Morisky Medication Adherence Scaler [ Time Frame: 12 weeks ]
9 item Morisky self report measure on medication adherence
Medication diaries, Self-reported Medication-taking Scale, and the ACTG Adherence Follow-up Questionnaire
Not Provided
Not Provided
 
Managing Medications
Improving Adherence to Antiretroviral Therapy
The primary aim of this study is to compare the effect of an individualized adherence intervention (TI) and a structured adherence intervention (TS) to usual care on adherence to antiretroviral therapy in persons infected with HIV (PWHIV).
The primary aim of this study is to compare the effect of an individualized adherence intervention (TI) and a structured adherence intervention (TS) to usual care on adherence to antiretroviral therapy in persons infected with HIV (PWHIV). The secondary aims address the relationship between adherence and quality of life (QOL), and between adherence and clinical response. The exploratory aims focus on examining the effect of self-efficacy on the relationship between the intervention and adherence, the effect of adherence on the relationship between self-efficacy and outcomes (clinical response and quality of life), as well as the effects of symptoms, alcohol and/or drug use, chronic interpersonal problems, mood, social support, optimism, perceived burden of medication regimen, perceived stigma, purpose in life, co-morbidity, personality, literacy, and intimate partner abuse on self-efficacy, and psychometric analyses of the instruments. The sample of 300 (plus 51 dropouts) PWHIV who are taking antiretroviral therapy and without cognitive dysfunction will be randomly assigned to one of two treatment arms. Those individuals who are deemed to be 100% adherers (approximately 25-50) will be assigned to the control group, but will be followed separately as a natural history substudy and interviewed. Data will be collected at baseline, post-treatment, post-maintenance, post-booster, and 18 months. Electronic event monitors, diaries, the Self-reported Medication-taking Scale, and the ACTG Adherence Follow-up Questionnaire will be used to assess adherence. The Digit Vigilance Test will be used to assess the effect of sustained attention on adherence. QOL will be measured using the MOS-HIV, the Satisfaction with Life Scale, and the Perception of Illness Visual Analogue Scale. Clinical response will be assessed using viral load, CD4 T-cell count, AIDS defining conditions, and hospitalizations. Variables influencing self-efficacy (measured with an investigator-developed Self-efficacy Scale) will be examined: symptoms ( CRCD Symptom Checklist), alcohol and/or drug use (AUDIT), chronic interpersonal problems (IIP), social support (Interpersonal Support Evaluation List), optimism (Life Orientation Test), anxiety (Beck Anxiety Inventory) and Beck Depression Inventory II), perceived burden of regimen (visual analog scales), perceived stigma (Perceived Stigma of HIV Scale), purpose in life (Purpose in Life Scale), co-morbidity (CRCD Co-Morbidity Scale), personality characteristics (NEO-FFI), health literacy (Test of Functional Health Literacy in Adults), knowledge about HIV medication adherence (HIV Medication Adherence Knowledge), and intimate partner abuse (Abuse Assessment Screen). A repeated measures model with planned comparisons will be used to test the hypotheses for the primary aim. Structural equation modeling will be used to examine the relationships identified in the secondary and exploratory aims. PWHIV who adhere to their therapy may live longer, require fewer hospitalizations, and have an improved QOL.
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
HIV Infections
Behavioral: Problem solving counseling
Telephone nurse counseling behavioral intervention focused on problem solving.
  • Experimental: Structured
    Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
    Intervention: Behavioral: Problem solving counseling
  • No Intervention: Usual Care
    Control arm
  • Experimental: Inidividualized
    Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
    Intervention: Behavioral: Problem solving counseling
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
349
December 2009
December 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must be able to give informed consent,
  • be 18 years or older,
  • be taking antiretroviral therapy,
  • be able to speak and understand English,
  • have a telephone or access to a telephone,
  • and be living in a private residence or apartment in the community as opposed to a personal care/nursing home.

Exclusion Criteria:

  • significant cognitive impairment,
  • blind
  • motor impairment of their upper extremities
  • if another person in their household was or is currently enrolled in the study
  • the HDS that we will use to screen for cognitive impairment cannot be used with individuals who have these physical problems
  • Those with a hearing impairment who do not have a modified telephone to enhance their hearing will be excluded since they are unable to participate in the telephone delivered interventions or data collection.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00222716
2R01NR004749( U.S. NIH Grant/Contract )
Yes
Not Provided
Plan to Share IPD: No
Plan Description: There is not plan to share data specifically but the data has been shared with the Mach14 Collaborative. Entire data set has been shared with the Collaborative.
Judith Erlen, University of Pittsburgh
University of Pittsburgh
National Institute of Nursing Research (NINR)
Principal Investigator: Judith A Erlen, PHD University of Pittsburgh
Study Director: Lisa K Tamres, MS University of Pittsburgh School of Nursing
University of Pittsburgh
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP